An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Genprex to Participate in Upcoming Investor Conference in March
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Genprex, a clinical-stage gene therapy company, will present at the BIO Europe Spring Investor Conference from March 28-31, 2022. President and CEO Rodney Varner will discuss the company's innovative gene therapies targeting cancer and diabetes. Genprex's lead product, REQORSA (quaratusugene ozeplasmid), aims to treat non-small cell lung cancer by utilizing the ONCOPREX Nanoparticle Delivery System, which is the first systemic gene therapy for cancer in humans. The presentation will be available on-demand, and Varner will also engage in virtual one-on-one meetings with participants.
Positive
None.
Negative
None.
Investor presentation to highlight the Company’s gene therapies for cancer and diabetes
AUSTIN, Texas--(BUSINESS WIRE)--
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Varner, will provide an overview of the Company’s gene therapies for cancer and diabetes to investors at the 2022 BIO Europe Spring Investor Conference.
Conference Details:
Event:BIO Europe Spring Investor Conference Conference Dates:March 28-31, 2022 Presentation Time: Available on-demand throughout duration of the conference
Presenter:Rodney Varner, President and Chief Executive Officer
Conference Registration: https://bit.ly/3hNGjcW
At the event, Mr. Varner will be available to participate in virtual one-on-one meetings with registered participants. A recording of this presentation will be available for replay on Genprex’s website for a period of time.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. In 2021, the FDA granted Fast Track Designation for REQORSA for NSCLC in combination therapy with Merck & Co’s Keytruda® (pembrolizumab) for patients whose disease progressed after treatment with Keytruda.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K and “Part II, Item 1A” of Genprex’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals, including the extent and impact of the COVID-19 pandemic; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
What is Genprex presenting at the BIO Europe Spring Investor Conference 2022?
Genprex will present its gene therapies for cancer and diabetes at the BIO Europe Spring Investor Conference from March 28-31, 2022.
Who is the CEO of Genprex?
Rodney Varner is the President and CEO of Genprex.
What is the focus of Genprex's gene therapy research?
Genprex focuses on developing therapies for cancer and diabetes, leveraging innovative gene delivery systems.
What is Genprex's lead product candidate?
Genprex's lead product candidate is REQORSA (quaratusugene ozeplasmid), which targets non-small cell lung cancer.
What unique delivery system does Genprex use?
Genprex utilizes the ONCOPREX Nanoparticle Delivery System for its gene therapies, believed to be the first systemic gene therapy delivery platform for cancer.
Where can I find the presentation by Genprex?
The presentation will be available for on-demand viewing on Genprex's website during the conference.
Has the FDA granted any designations for Genprex's products?
Yes, the FDA has granted Fast Track Designation for Genprex's REQORSA for non-small cell lung cancer in combination with AstraZeneca's Tagrisso and Merck's Keytruda.